10–12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapy

Katoch, Kiran; Katoch, Vishwa Mohan; Natrajan, Mohan; Sreevatsa,; Gupta, U. D.; Sharma, V. D.; Shivanavar, Channappa T

doi:10.1016/j.vaccine.2004.03.037

Cited by 22 publications

(19 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some reports warns about the risk of the onset of reactions, especially type 1 reactions; other reports, in turn, show that, rather than causing reactions, immunotherapy may reduce the time of reactions and of treatment to achieve bacillary clearance. 120,121 …”

Section: Preventionmentioning

confidence: 99%

Leprosy: a review of laboratory and therapeutic aspects - Part 2

Lastória

Abreu

2014

An. Bras. Dermatol.

View full text Add to dashboard Cite

Leprosy is a chronic infectious condition caused by Mycobacterium leprae(M. leprae). It is endemic in many regions of the world and a public health problem in Brazil. Additionally, it presents a wide spectrum of clinical manifestations, which are dependent on the interaction between M. leprae and host, and are related to the degree of immunity to the bacillus. The diagnosis of this disease is a clinical one. However, in some situations laboratory exams are necessary to confirm the diagnosis of leprosy or classify its clinical form. This article aims to update dermatologists on leprosy, through a review of complementary laboratory techniques that can be employed for the diagnosis of leprosy, including Mitsuda intradermal reaction, skin smear microscopy, histopathology, serology, immunohistochemistry, polymerase chain reaction, imaging tests, electromyography, and blood tests. It also aims to explain standard multidrug therapy regimens, the treatment of reactions and resistant cases, immunotherapy with bacillus Calmette-Guérin (BCG) vaccine and chemoprophylaxis.

show abstract

Section: Preventionmentioning

confidence: 99%

Leprosy: a review of laboratory and therapeutic aspects - Part 2

Lastória

Abreu

2014

An. Bras. Dermatol.

View full text Add to dashboard Cite

show abstract

“…Katoch et al . have used BCG at 6‐month intervals in bacilliferous leprosy patients and achieved faster clearance of bacilli assessed by mouse footpad and bacillary adenosine triphosphate content.…”

Section: Discussionmentioning

confidence: 99%

Lepromatous leprosy treated with combined chemotherapy and immunotherapy (injection BCG): three case reports

Lakshmi

Srinivas

2013

Int J Dermatol

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4] Clinical improvement with accelerated bacterial clearance and histological up grading using MIP vaccine has been reported in adult cases with high bacillary load. [5][6][7] However, there is lack of information in borderline pediatric leprosy which is characterized by a state of shifting immunity and would therefore be ideally suited to such observations. MIP in general shows a good response in adulthood leprosy but its role as adjuvant with chemotherapy on clinical recovery of pediatric leprosy has not been reported so far.…”

Section: Introductionmentioning

confidence: 99%